CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 546 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
ZNL-05-044
ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay.Formula:C21H22Cl2N6OSPurity:98%Color and Shape:SolidMolecular weight:477.41CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Formula:C40H29ClIrN5OColor and Shape:SolidMolecular weight:823.36CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Formula:C24H32F3N5O2Color and Shape:SolidMolecular weight:479.548CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Formula:C22H25ClN8OColor and Shape:SolidMolecular weight:452.95Anticancer agent 264
Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.Formula:C23H18ClF5N6OColor and Shape:SolidMolecular weight:524.87SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurity:99.96%Color and Shape:SolidMolecular weight:238.28PROTAC CDK9 degrader-7
CAS:PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (Formula:C43H50Cl2N8O9Color and Shape:SoildMolecular weight:893.81CP-07
CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formationFormula:C45H48N6O8Purity:98%Color and Shape:SolidMolecular weight:800.9JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.161CDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Formula:C20H21F2N9Color and Shape:SolidMolecular weight:425.448NU6102
CAS:NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.Formula:C18H22N6O3SPurity:99.76%Color and Shape:SolidMolecular weight:402.47LDC4297
CAS:LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.Formula:C23H28N8OPurity:98.25%Color and Shape:SolidMolecular weight:432.52Ribociclib hydrochloride
CAS:Ribociclib hydrochloride (LEE011 HCl) is a selective, orally active cyclin-dependent kinase CDK4/6 inhibitor (IC50=10/39 nM) that inhibits proliferation.Formula:C23H31ClN8OPurity:99.87%Color and Shape:SolidMolecular weight:471CDK5-IN-3
CAS:CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.Formula:C22H26N4OPurity:98.21%Color and Shape:SolidMolecular weight:362.47Palbociclib-d8
CAS:Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.Formula:C24H21D8N7O2Purity:98%Color and Shape:SolidMolecular weight:455.58PROTAC CDK9 Degrader-1
CAS:PROTAC CDK9 Degrader-1 is a selective PROTAC-based CDK9 degrader, composed of a Cereblon ligand and a CDK ligand.Formula:C33H35N5O7Purity:95.1%Color and Shape:SolidMolecular weight:613.66TG-693
CAS:TG-693, Oral CLK1 inhibitor, promotes exon 31 skipping of dystrophin gene, inhibits CLK1 substrate phosphorylation, for Duchenne muscular dystrophy.Formula:C12H9N3Purity:99.81%Color and Shape:SolidMolecular weight:195.23NCT02
CAS:NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.Formula:C17H16N2O2SColor and Shape:SolidMolecular weight:312.39Palbociclib hydrochloride
CAS:Palbociclib hydrochloride is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor for breast and hepatocellular carcinoma.Formula:C24H31Cl2N7O2Purity:99.89%Color and Shape:SolidMolecular weight:520.46
